| Stereochemistry | ACHIRAL |
| Molecular Formula | C22H30N6O3S |
| Molecular Weight | 458.577 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNS(=O)(=O)CC1=CC=C2NC=C(CCCN3CCN(CC3)C4=NC=NC=C4OC)C2=C1
InChI
InChIKey=WRZVGHXUPBWIOO-UHFFFAOYSA-N
InChI=1S/C22H30N6O3S/c1-23-32(29,30)15-17-5-6-20-19(12-17)18(13-25-20)4-3-7-27-8-10-28(11-9-27)22-21(31-2)14-24-16-26-22/h5-6,12-14,16,23,25H,3-4,7-11,15H2,1-2H3
| Molecular Formula | C22H30N6O3S |
| Molecular Weight | 458.577 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Avitriptan (BMS-180048), a new 5-HT 1B/1D receptor agonist, has been studied in phase II clinical trials in patients with migraine headaches. Later experiments have confirmed antimigraine activity together with coronary side-effect potential that is why further studies were discontinued.
Originator
Approval Year
PubMed
|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
TARGET -> AGONIST |
|
||
|
|
TARGET -> AGONIST |
|
Showing 1 to 3 of 3 entries
